Single sST2 protein measurement predicts adverse outcomes at 1-year follow-up in patients with chronic heart failure

Polskie Archiwum Medycyny Wewnetrznej

Volumn 124, Issue 9, 2014, Pages 452-458

  Sobczak, Sebastian ^a   Wojtczak Soska, Karolina ^a   Ciurus, Tomasz ^a   Sakowicz, Agata ^a   Pietrucha, Tadeusz ^a   Lelonek, Małgorzata ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Chronic heart failure; Prognosis; sST2; Systolic dysfunction

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; SST2 PROTEIN; UNCLASSIFIED DRUG; BRAIN NATRIURETIC PEPTIDE; CYCLO(ACETYLCYSTEINYL-PROLYL-GLYCYL-CYSTEINAMIDE); CYCLOPEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); SOMATOSTATIN RECEPTOR;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CARDIAC PATIENT; DISEASE MARKER; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN FOLDING; RECEIVER OPERATING CHARACTERISTIC; BLOOD; CHRONIC DISEASE; MIDDLE AGED; PREDICTIVE VALUE; PROGNOSIS;

AGED; BIOLOGICAL MARKERS; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PEPTIDES, CYCLIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, SOMATOSTATIN;

EID: 84907688997     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.2403     Document Type: Article

References (25)

1. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. 2008; 7: 827-840.
2. Bhardwaj A, Januzzi JL. ST2: a novel biomarker for heart failure. Expert Rev Mol Diagn. 2010; 10: 459-464.
3. Mueller T, Dieplinger B. The Presage ST2 Assay: analytical considerations and clinical applications for high-sensitivity assay for measurement of soluble ST2. Expert Rev Mol Diagn. 2013; 13: 13-30.
4. Shimpo M, Morrow DA, Weinberg EO, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004; 109: 2186-2190.
5. Januzzi JL, Peacock WF, Maisel AS, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol. 2007; 50: 607-613.
6. Bayes-Genis A, de Antonio M, Vila J, et al. Head-to-head comparison of two myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 vs. Galectin-3. J Am Coll Cardiol. 2014; 63: 158-166. doi: 10.1016/j.jacc.2013.07.087.
7. Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007; 116: 1482-1487.
8. Rywik TM, Koziarek J, Piotrowski W, et al. Trends in heart failure mortality in Poland between 1980 and 2010. Pol Arch Med Wewn. 2013; 123: 664-671.
9. Klabnik A, Murin J. Chronic heart failure in woman. Pol Arch Med Wewn. 2012; 122 Suppl 1: 42-46.
10. Michalik C, Matusik P, Nowak J, et al. Heart failure, comorbidities, and polypharmacy among elderly nursing home residents. Pol Arch Med Wewn. 2013; 123: 170-175.
11. Böhm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010; 376: 886-894.
12. von Haehling S, Schefold JC, Jankowska E, et al. Leukocyte redistribution: effects of beta blockers in patients with chronic heart failure. PLoS One. 2009; 4: e6411.
13. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008; 358: 2148-2159.
14. Maisel A, Mueller C, Adams K, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008; 10: 824-839.
15. Ky B, French B, Levy WC, et al. Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail. 2012; 5: 183-190.
16. Pascual-Figal DA, Ordoñez-Llanos J, Tornel PL, et al. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol. 2009; 54: 2174-2179.
17. Ky B, French B, McCloskey K, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail. 2011; 4: 180-187.
18. Weinberg EO, Shimpo M, Hurwitz S, et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. 2003; 107: 721-726.
19. Boisot S, Beede J, Isakson S, et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail. 2008; 14: 732-738.
20. Bayes-Genis A, de Antonio M, Galán A, et al. Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Fail. 2012; 14: 32-38.
21. Lupón J, de Antonio M, Galán A, et al. Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment. Mayo Clin Proc. 2013; 88: 234-243.
22. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012; 33: 1787-1847.
23. Bao Y, Shang X, Zhou L, et al. Relationship between N-terminal pro-B-type natriuretic peptide levels and metabolic syndrome. Arch Med Sci. 2011; 7: 247-256.
24. Wojtczak-Soska K, Pietrucha T, Sakowicz A, Lelonek M. Soluble ST2 protein in chronic heart failure is independent of traditional factors. Arch Med Sci. 2013; 9: 21-26.
25. Wu AH, Wians F, Jaffe A. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results. Am Heart J. 2013; 165: 995-999.